In:
Stroke, Ovid Technologies (Wolters Kluwer Health), Vol. 49, No. Suppl_1 ( 2018-01-22)
Abstract:
Introduction and Hypothesis: To evaluate the effect of Human Urinary Kallidinogenase (HUK) regarding the changes to brain metabolites in patients with acute ischemic cerebral infarction (AIS) by magnetic resonance spectroscopy. Methods: From 1, 2014 to 10, 2016, 57 patients with AIS who having MRI within 72 hours of onset of symptoms were randomly divided into an observation group and a control group. The control group was given standard care while the observation group was treated with HUK in additional to standard care. The levels of N-acetyl aspartate (NAA) and creatine (Cr) in the brain were measured by multi-voxel Proton magnetic resonance spectroscopy (MRS) before and one week after intervention The National Institutes of Health Stroke Scale (NIHSS) was performed using the Improved Rankin scale (mRA) score, Barthel index (BI) to evaluate clinical efficacy. The obtained data were assessed using percentages, t test, and F test in the SPSS 19.0 software. Results: The values of NAA, NAA/Cr, the NIHSS score, and the mRS were not significantly different between the two groups (P 〉 0.05) at baseline before the treatment. One week post-observation, the values of both NAA and NAA/Cr in the central infarcted area were lower than before in both groups before the observation P 〈 0.05). The NAA and NAA/Cr in the peripheral infarcted areas of the observation group were higher than those in the control group , and the increase of NAA and NAA / Cr in the observation group was higher than that in the control group ( HUK group vs. Control group: NAA, NAA/Cr. P 〈 0.05: respectively). In addition, the NIHSS score, mRS score, and BI index were higher in the observation group than in the control group (P 〈 0.05). Conclusion: Treating patients with AIS with HUK can improve both the brain metabolic profile as well as patient’s clinical outcomes.
Type of Medium:
Online Resource
ISSN:
0039-2499
,
1524-4628
DOI:
10.1161/str.49.suppl_1.TP49
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2018
detail.hit.zdb_id:
1467823-8
Bookmarklink
